GRFS
Strong BuyFull HouseAI concernGrifols, S.A. · Healthcare · Spain · $4.9B cap · $4.7M/day traded
$7.45 -0.7% · close 22 Oct · scored 23 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Strong on the numbers, but the AI review named a specific concern. Its reason is in the AI review below.
As of 23 Oct 2026, MoatMap's StockRank for Grifols, S.A. (GRFS) is 83/100, ranked against 24,000+ stocks in 35 markets (Quality 50, Value 75, Momentum 56, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Grifols is a major plasma-derived medicines producer, and earnings have recovered strongly. However, Canada's regulator has suspended one of Grifols' plasma collection licences over quality-management problems. That is a specific regulatory failure in the plasma supply chain on which the whole business depends. It adds to a history of governance and disclosure controversy and a heavily indebted balance sheet. In a higher-for-longer rate environment, that debt load is a more serious burden.
ABOUT GRIFOLS, S.A.
Read
Grifols, S.A. is a global healthcare company specializing in plasma-derived medicines, diagnostics, and hospital pharmacy solutions. It is one of the world's leading producers of plasma-derived therapies, underpinned by a vertically integrated plasma collection and manufacturing network. Grifols is a critical supplier of life-saving medicines for rare and chronic conditions, supported by significant R&D investment.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.9B | 6.8B | 7.4B | 8.1B | 8.4B | 14.3% | 8.3B | 8.6B | 9.1B | 4.2% |
| EPS | 0.27 | 0.91 | 0.27 | 0.68 | 1.74 | 59.4% | 0.77 | 2.34 | 2.91 | 29.3% |
| Shares | 687.6M | 258.2M | 258.2M | 258.2M | 258.2M | -62.4% | 258.2M | — | — | — |
| Debt | 9.3B | 10.9B | 12.3B | 11.3B | 10.7B | 3.5% | 10.5B | — | — | — |
| Equity | 5.5B | 6.3B | 6.0B | 6.6B | 5.9B | 1.7% | — | — | — | — |
| Op CF | 597.0M | -1.6M | 243.0M | 1.0B | 1.2B | 18.4% | 1.2B | — | — | — |
| Inv CF | -854.1M | -2.2B | -441.2M | 992.2M | -648.4M | — | — | — | — | — |
| Fin CF | 2.3B | -184.7M | 192.6M | -1.5B | -592.4M | — | — | — | — | — |
No new 52-week low for 15 weeks, 8% above that low, but not back above a rising 50-day average.
The Momentum score still reads 56: it looks back six months, so it has not caught up with this fall.
Calmer than 69% of stocks we rank over the past year (32% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GRFS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GRFS | Grifols, S.A.(you) | $4.9B | 83 | Strong Buy |
| ROVI.MC | Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 77 | Buy |
| ALM.MC | Almirall, S.A. | $2.6B | 67 | Buy |
| CBAV.MC | Clínica Baviera, S.A. | $1.0B | 91 | Strong Buy |
| FAE.MC | Faes Farma, S.A. | $1.6B | 66 | Buy |
| PHM.MC | Pharma Mar, S.A. | $1.4B | 54 | Hold |
| PRM.MC | Prim, S.A. | $242M | 97 | Strong Buy |
| RJF.MC | Laboratorio Reig Jofre, S.A. | $251M | 59 | Hold |
| VYT.MC | Vytrus Biotech, S.A. | $127M | 66 | Buy |
| LAB.MC | Labiana Health, S.A. | $51M | 68 | Buy |
Peer medians: ROE 11.2% · P/E 19.0x · Gross margin 64.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.